Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2951-2957

  Stevens, Miguel ^a   Pannecouque, Christophe ^a   De Clercq, Erik ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ASPARAGINE; CYSTEINE; EFAVIRENZ; GLUTAMINE; GUANINE; HISTIDINE; ISOLEUCINE; JPL 10; JPL 107; JPL 110; JPL 133; JPL 146; JPL 150; JPL 27; JPL 30; JPL 71; JPL 74; JPL 78; LAMIVUDINE; LYSINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; PYRIDINE 1 OXIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TYROSINE; UC B3096; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PRIORITY JOURNAL; REVERSE TRANSCRIPTASE GENE; VIRUS CULTURE; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELLS, CULTURED; GENOTYPE; HIV-1; HIV-2; HUMANS; MUTATION; PYRIDINES; RNA-DIRECTED DNA POLYMERASE;

EID: 0041421236     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2951-2957.2003     Document Type: Article

References (14)

1. Balzarini, J., M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. 1992. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by a novel HIV-1-specific nucleoside analogue [2′, 5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl] -3′-espiro-5″-(4″-amino-1″, 2″-oxathiole-2″, 2″-dioxide) thymine (TSAO-T). J. Biol. Chem. 267:11831-11838.
2. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors result in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
3. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, L. Vrang, J. Walbers, H. Zhang, B. Öberg, A.-M. Vandamme, M.-J. Camarasa, and E. De Clercq. 1993. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253.
4. Balzarini, J. 1999. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 58:1-27.
5. Balzarini, J., M. Stevens, G. Andrei, R. Snoeck, R. Strunk, J. B. Pierce, J. A. Lacadie, E. De Clercq, and C. Pannecouque. 2002. Pyridine oxide derivatives: structure-activity relationship for inhibition of human immunodeficiency virus and cytomegalovirus replication in cell culture. Helvetica Chimica Acta 85:2961-2974.
6. Barré-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 220:868-871.
7. De Clercq, E. 1999. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco. 54:26-45.
8. De Clercq, E. 2002. New anti-HIV agents and targets. Med. Res. Rev. 22:531-565.
9. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
10. Fitzgibbon, J. E., S. Mazar, and D. T. Dubin. 1993. A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retrovir. 9:833-838.
11. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
12. Rey, M.-A., B. Kurst, A. G. Laurent, D. Guétard, L. Montagnier, and A. G. Hovanessian. 1989. Characterization of an HIV-2-related virus with a smaller sized extra-cellular envelope glycoprotein. Virology 173:258-267.
13. Vartanian J.-P., A. Meyerhans, B. Åajö, and S. Wain-Hobson. 1991. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65:1779-1788.
14. Vartanian J.-P., A. Meyerhans, M. Sala, and S. Wain-Hobson. 1994. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 91:3092-3096.